|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Metabolic Syndrome/Insulin Resistance Syndrome/Pre-Diabetes |
Prevalence of Body Iron Excess in the Metabolic Syndrome
1 Department of Clinical and Experimental Medicine, University of Verona, Verona, Italy
2 Institute of Clinical Chemistry, University of Verona, Verona, Italy
Address correspondence and reprint requests to Domenico Girelli, MD, Department of Clinical and Experimental Medicine, University of Verona, Policlinico G.B. Rossi, 37134 Verona, Italy. E-mail: domenico.girelli@univr.it
Abbreviations: ATPIII, Adult Treatment Panel III • HIO, hepatic iron overload • hs-CRP, high-sensitivity C-reactive protein • IR-HIO, insulin resistance–associated HIO
| The first 20% of the full text of this article appears below. |
 |
INTRODUCTION |
|---|
The metabolic syndrome, clinically defined by the Adult Treatment Panel III (ATPIII) (1), affects
25% of western adults (2). The metabolic syndrome is closely linked to insulin resistance and implies an increased cardiovascular risk (3,4). Accumulating evidence suggests a link between body iron excess and insulin metabolism (5). Studies have shown an association between serum ferritin and one or more metabolic syndrome feature (6–11). Moreover, a syndrome characterized by hepatic iron overload (HIO) associated with insulin resistance features (insulin resistance–associated HIO [IR-HIO]), unrelated to genetic hemochromatosis, has been described (12,13). IR-HIO currently represents the most frequent indication to venesection in referral care units for iron overload (14). Data on the other side of the phenomenon, namely the prevalence of a potentially relevant iron overload in subjects selected for having metabolic syndrome, are scanty.
|
RESEARCH DESIGN AND METHODS |
|---|
Within the registry of the Verona Heart Project (15), we identified metabolic syndrome subjects according to ATPIII because of three of more of the following: 1) fasting glucose
110 mg/dl or antidiabetes medication, 2) hypertension (blood pressure 135/85 mmHg or medication), 3) triglycerides 150 mg/dl, 4) HDL cholesterol <40 mg/dl in men and <50 mg/dl in women, and 5) obesity (BMI 27 kg/m2 instead of waist circumference, due to unavailability of waist circumference measurement in all subjects). An age-matched control group was extracted from the registry, requiring the absence of either metabolic syndrome or any evidence of cardiovascular disease. |
RESULTS |
|---|
|
CONCLUSIONS |
|---|
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Dongiovanni, L. Valenti, A. Ludovica Fracanzani, S. Gatti, G. Cairo, and S. Fargion Iron Depletion by Deferoxamine Up-Regulates Glucose Uptake and Insulin Signaling in Hepatoma Cells and in Rat Liver Am. J. Pathol., March 1, 2008; 172(3): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Swaminathan, V. A. Fonseca, M. G. Alam, and S. V. Shah The Role of Iron in Diabetes and Its Complications Diabetes Care, July 1, 2007; 30(7): 1926 - 1933. [Full Text] [PDF]
|
|
|
|
|
|
Z. Shi, X. Hu, B. Yuan, X. Pan, H. E. Meyer, and G. Holmboe-Ottesen Association Between Serum Ferritin, Hemoglobin, Iron Intake, and Diabetes in Adults in Jiangsu, China Diabetes Care, August 1, 2006; 29(8): 1878 - 1883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C E Wrede, R Buettner, L C Bollheimer, J Scholmerich, K-D Palitzsch, and C Hellerbrand Association between serum ferritin and the insulin resistance syndrome in a representative population Eur. J. Endocrinol., February 1, 2006; 154(2): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |